Vivace adds new CEO, CBO ahead of ph. 3 trial—Chutes & Ladders
Vivace Therapeutics appoints new CEO and Chief Business Officer as the company prepares for a pivotal Phase 3 trial.
Vivace Therapeutics
Private
Company Info
Recent News
Vivace Therapeutics Strengthens Leadership Team as It Prepares to Advance VT3989, the First TEAD Inhibitor to enter Phase 3 Clinical Trials, as the Leading Treatment for Mesothelioma
Vivace Therapeutics is strengthening its leadership team as it prepares to advance VT3989, the first TEAD inhibitor to enter Phase 3 trials for mesothelioma.